In the last trading session, 1.41 million shares of the Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) were traded, and its beta was 2.65. Most recently the company’s share price was $27.45, and it changed around $0.86 or 3.23% from the last close, which brings the market valuation of the company to $739.23M. ARCT currently trades at a discount to its 52-week high of $45.00, offering almost -63.93% off that amount. The share price’s 52-week low was $17.52, which indicates that the current value has risen by an impressive 36.17% since then. We note from Arcturus Therapeutics Holdings Inc’s average daily trading volume that its 3-month average coming to 573.45K.
Arcturus Therapeutics Holdings Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 1 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended ARCT as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Arcturus Therapeutics Holdings Inc is expected to report earnings per share of -1.6 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information
Instantly ARCT has showed a green trend with a performance of 3.23% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -12.94% year-to-date, but still down -13.13% over the last five days. On the other hand, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is -8.04% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $68.8, which translates to bulls needing to increase their stock price by 60.1% from its current value. Analyst projections state that ARCT is forecast to be at a low of $14 and a high of $140.
Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts
Arcturus Therapeutics Holdings Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -15.30 percent over the past six months and at a -120.60% annual growth rate that is well below the industry average of 15.20%. The year-over-year growth rate is expected to be 7.00%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 21.7M in revenue for the current quarter. 7 analysts expect Arcturus Therapeutics Holdings Inc to make 46.7M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.52M and 45.14M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 106.30%. Forecasts for the next quarter put sales growth at 3.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 12.40%.
ARCT Dividends
Arcturus Therapeutics Holdings Inc’s next quarterly earnings report is expected to be released in July.
